Chronic hepatitis by Hift, R.J.
It is important to establish the aetiology of acute viral
hepatitis in order to treat patients and their contacts
appropriately and to limit the spread of infection. Although
a careful clinical history and biochemical markers are
important, diagnosis depends on specific serological testing.
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Most cases of hepatitis which are due to viral infection or
drug injury will resolve promptly. Indeed, in most instances
elevated transaminases may be expected to return to
normal levels within 3 months. However, in some instances
inflammation does not settle but becomes established as a
chronic illness. Although the patient may be asymptomatic,
the transaminases are intermittently or permanently
elevated, liver biopsy shows continuing damage, and there
may be evidence of ongoing viral replication. The whole
process is associated with a high risk of progression to
cirrhosis, chronic liver failure and hepatocellular carcinoma.
These then are the parameters which define the entity of
chronic hepatitis.
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Clinically the disorder is defined by demonstrating·
evidence of inflammation that has been present for at least 6
months.' The terminology of chronic hepatitis is confusing.
For many years the terms chronic persistent hepatitis (CPH)
and chronic active hepatitis (CAH) have been employed.'.2
The two were distinguished histologically by the degree and
morphological pattern of inflammation. Thus, in CPH
inflammation was confined to the portal tracts with no
periportal inflammation or inflammation within the hepatic
lobule, whereas in CAH hepatocyte necrosis and fibrosis
were evident. The distinction was believed to have important
clinical and prognostic consequences, CPH denoting a
relatively benign disease, whereas CAH was likely to
progress to cirrhosis. The terms were originally applied to
the auto-immune variety of chronic hepatitis, but have been
extended to other forms of hepatitis, and to chronic viral
hepatitis in particular, where the distinction is less useful.3
Histological changes may not be uniformly distributed
throughout the liver - thus being open to sampling error -
and may also change with time; hence demonstration of the
features of CPH now offer no guarantee that the course will
be benign, or that a repeat biopsy will not show aggressive
changes. Indeed, it is the presence of virus and its
replicative status that will determine the progression of the
disease,' and histology is at best an indirect reflection of
this. Thus the terms CPH and chronic lobular hepatitis (a
later addition to the family) are now discouraged. It is
appropriate to consider all cases as chronic hepatitis (CH),
and to qualify the term further by cause, severity and
histological appearance. Thus one may speak of mild CAH
secondary to chronic hepatitis B viral infection with
inflammation limited to the portal tracts, or of severe auto-
immune CAH showing hepatocyte necrosis and fibrosis
linking adjacent portal tracts.
Causation
The important causes of chronic hepatitis are listed in
Table I. The major categories are type Band C viral
hepatitis, auto-immune chronic hepatitis (AICH) and drug-
induced chronic hepatitis. Although both primary scierosing
cholangitis (PSC) and primary biliary cirrhosis (PBC) may
present with some of the histological features of CH, they
are usually distinguished from AICH by their other
characteristic features. There are in addition a few other





Overlap with primary biliary cirrhosis, primary sclerosing
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conditions characterised by ongoing hepatic inflammation,
some with specific reversible causes which must be
identified and treated. These include alcoholic
steatohepatitis, non-alcoholic steatohepatitis, Wilson's
disease, a,-antitrypsin deficiency and the iron overload
states haemosiderosis and haemochromatosis.
Several of these conditions are discussed in more detail
elsewhere in this issue. Those aspects relevant to their
diagnosis are described below.
Viral hepatitis B
Hepatitis B virus infection is the most common cause of
chronic hepatitis, and indeed of cirrhosis, in the world.'
Recent findings have yielded insights into the biological
mechanisms which predispose to chronicity in hepatitis B
infection. Chronic hepatitis is established where the host
immune response is sufficiently aggressive to result in
hepatocyte damage, yet inadequate to eradicate the virus."
Were the immune response stronger, the virus would be
eradicated and the disease self-limiting; were it less efficient,
tolerance would ensue with viral persistence but no liver
damage. Thus chronic hepatitis appears to arise in those
people whose immune response falls between these two
extremes.
Although symptoms and signs are nonspecific,
extrahepatic manifestations of HBV infection such as
arthritis or glomerulonephritis may occasionally point to
hepatitis B as the cause of a chronic liver problem. The
hallmark of chronic hepatitis B is persistence of hepatitis B
antigenaemia. CH may be diagnosed where HBe antigen or
HBs antigen are present for more than 6 months. Since, in
acute infection, HBe antigen is normally cleared as early as
2 weeks after the onset of the illness, persistence of this
antigen for more than 3 months strongly suggests that the
infection has entered a chronic phase. HBs antigen is almost
invariably present in chronic hepatitis B. Most cases of
chronic hepatitis will also be HBe antigen-positive; the
presence of this antigen always denotes active viral
replication and the continuing liver damage, albeit perhaps
mild.1 Increasingly, however, HBe antigen-negative mutant
viruses are being recognised, which fail to express HBe
antigen (and usually demonstrate anti-HBe antibody) yet
cause severe and rapidly progressive liver damage. Thus the
absence of HBe antigen does not exclude hepatitis B as the
cause of a chronic hepatitis. In such cases the diagnosis
can be confirmed by quantitating HBV DNA, since high
levels of this reflect viral replication. Determination of HBV
DNA polymerase activity or of low-titre IgM anti-HBc
antibody may also confirm HBV as the cause of the chronic
hepatitis, but are not routinely available. These three
markers of viral activity are becoming increasingly important
in determining the need for antiviral therapy with a-interferon
and in assessing a patient's response to it.
The diagnosis of chronic hepatitis B is in most instances
_readily made on biopsy_ The degree of hepatic inflammation
and damage varies. Typical features are the presence of
ground-glass hepatocytes which stain positively with orcein"
Immunohistochemical techniques may show the presence of
surface antigen and HBc antigen in the hepatocytes.9 Newer
techniques of in situ hybridisation may demonstrate the
genomic sequences of viral DNA in infected cells. Such
features confirm the presence of HBV in the liver; the effect
of the virus may be gauged by assessing the extent of the
accompanying inflammation, necrosis and fibrosis.
Unfortunately some patients with hepatitis B CH fail all
these tests. Cases are reported where livers removed at
transplantation have proved to be infected with HBV, despite
the absence of all antigens and antibodies, negative
immunohistochemical tests and inconclusive histological
features despite an extensive search for the cause of the
liver disease before the operation.'o
Viral hepatitis C
Hepatitis C is currently the most frequent cause of chronic
hepatitis in the USA." A large proportion of cases preViously
labelled 'cryptogenic' CH have subsequently been identified
as cases of HCV infection. t2 A major feature of chronic
hepatitis C is that the disease itself is often mild, with low
levels of transaminases and few if any symptoms, whereas
the eventual outcome may be severe with cirrhosis and
chronic liver failure." Hepatitis C should perhaps be the first
diagnosis entertained in an otherwise asymptomatic-.
individual who is found to have a chronically but milcHy
elevated alanine transaminase (ALT). The diagnosis of
chronic hepatitis C is complicated by the poor specificity of
the serological tests employed for its diagnosis. The first-
generation enzyme-linked immunosorbent assays (ELlSAs)
which detected antibodies directed against the C1 00-3
antigen of HCV were of low sensitivity and specificity. They
are, however, still widely employed for screening of patients.
A positive result (which may represent a false positive in as
many as 70% of cases) demands a subsequent
confirmatory test; conversely, a negative result where the
clinical suspicion for hepatitis C, is high should be
independently checked with another test. t3 The second-
generation ELlSAs, which in addition to the C1 00-3
recognise antibodies directed against additional epitopes,
typically C33 and C22, have a much higher sensitivity and
specificity, but are still not entirely specific for hepatitis C.
Other confirmatory diagnostic tests include the synthetic
peptide ELlSAs and the recombinant immunoblot assay
(RIBA), which offer further increases in sensitivity and
specificity.t3 Unfortunately some patients will show
intermediate responses, with reactivity to some but not all of
the epitopes offered, and there remain a core of about 10%
of all cases with chronic HCV infection who remain
persistently antibody-negative. '3 The gold standard for the
diagnosis of chronic hepatitis C is therefore the
demonstration of RNA sequences by the polymerase chain
reaction (PCR). Physicians faced with a positive hepatitis C
result from a laboratory should never accept that result
without checking with the laboratory concerned by what
method the test was performed and whether confirmatory
tests are necessary.
The histological picture in chronic hepatitis C may vary
from mild to severe CAH and cirrhosis. Certain features on
biopsy are suggestive of hepatitis C infection. These
included lobular lymphoid aggregates, Iymphocyte infiltrate
of the sinusoids, focal bile duct damage, microvesicular fatty
change and hepatocytes showing eosinophilic granules with
eosinophilic bodies.1 The use of immunohistochemistry and
in situ hybridisation for the diagnosis of chronic hepatitis C
is as yet undetermined. Although patients showing more
severe inflammation are likely to proceed to cirrhosis more
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rapidly, the presence of apparently benign changes, which it
is tempting to label chronic persistent hepatitis, does not
imply a benign outcome; in many of these, progression to
cirrhosis is also noted."
Auto-immune chronic hepatitis
This is considerably less common than chronic hepatitis B
and C infection, but it is nevertheless not infrequently
encountered and was in fact the first form of chronic
nepatitis described."
AICH is commonly symptomatic. The age of onset is
usually between 10 and 40 years and 75% of patients are
female.' Symptoms include malaise, anorexia, fatigue,
amenorrhoea, and eventually features of portal hypertension
or liver failure. Occasionally AICH presents with fulminant
hepatic failure. Other forms of auto-immune disease such as
Sj6gren's syndrome and thyroiditis may be present. The
condition is often characterised by the presence of markedly
elevated transaminases, hypergammaglobulinaemia and a
variety of auto-antibodies. The serological features of AICH
are not uniform and allow subclassification of this disorder.
In type 1 AICH, antinuclear antibodies (ANA) are present, as
may be anti-smooth-muscle antibodies. Type 2 AICH is
characterised by the presence of anti-liver/kidney
microsomal (LKM1) antibodies without ANA. While up to
30% of patients also show positive antimitochondrial
antibodies, these are usually present in low titre and the
condition is easily distinguished from primary biliary
cirrhosis.'6 Although demonstration of the LE cell
phenomenon in some patients led to the term lupoid
hepatitis being applied as a synonym for AICH, there is no
association with systemic lupus erythematosus. A new
classification to be recommended shortly also allows a
seronegative subtype where no auto-antibodies are present
and there is no evidence for HCV infection, yet the presence
of hypergammaglobulinaemia, severe inflammation and a
positive response to corticosteroid therapy suggest that the
disorder is similar to the seropositive disease (P. Scheuer~
personal communication).
The association between chronic HCV infection and AICH
has attracted much interest. There is evidence that in some
patients with type 2 AICH (classified as type 2b) the immune
phenomena are probably triggered by hepatitis C virus
infection. The distinction is important in that such patients
may respond better to antiviral therapy with a-interferon
than to corticosteroidsH.'9
As with most forms of CH, the histological picture is
nonspecific. More active parenchymal inflammation as well
as larger numbers of plasma cells tend to suggest immune
hepatitis rather than viral hepatitis.]
In the absence of therapy, AICH is usually a progressive
disorder with a poor outcome. The condition often responds
well to immunosuppressive therapy with corticosteroids and
azathioprine. Where AICH is strongly suspected, a trial of
corticosteroid therapy is indicated.
Occasional patients with two other auto-immune disorders
of the liver, primary biliary cirrhosis and PSC, may show
evidence of an overlap syndrome with histological features -
indicative of CH in addition to the typical features of the
parent disorder. The clinical features, a disproportionate
increase in alkaline phosphatase, gamma-glutamyl
transpeptidase and 5' -nucleotidase, demonstration of
SAMJ
ARTICLES
histological changes, predominantly in the bile ducts, and an
abnormal cholangiogram may help to differentiate these
patients from those with pure AICH!O
Drug-induced chronic hepatitis
Although many drugs may induce an acute hepatitis, few
have been reported as causing a true chronic hepatitis
which might be confused with other forms of CH2'.22 One of
the more common offenders in South Africa is a-
methyldopa, which is widely prescribed for hypertension!3
Although methyldopa may be associated with benign
prolonged cholestasis" and a transient mild hepatotoxicity,"
it more commonly induces a severe CH which appears
indistinguishable from AICH both clinically and histologically.
Even ANA may be positive and the liver disease may be
accompanied by auto-immune haemolytic anaemia!6 The
disease will usually remit once methyldopa is withdrawn, but
some patients will develop fatal acute or subacute liver
failure, and rechallenge may be fatal." Long-term use of
oxyphenacetin,27 a component of laxatives, aRd
nitrofurantoin" may result in a similar syndrome of chronic
hepatitis. Other drugs which have been linked (but rarely)
with CH include isoniazid, sulphonamides, aspirin,
paracetamol, chlorpromazine and propylthiouracil.' There are
no specific features to allow a confident diagnosis of drug-
induced CH and the most appropriate test is an assessment
of the response to withdrawal of the drug.]
Conditions that may resemble
chronic hepatitis
Alcoholic liver disease
Alcohol abuse is a prominent cause of persistently
disordered transaminases. The histological changes are
usually sufficiently typical to point to alcohol as the cause.
Occasional patients, however, show histological lesions
suggestive of CH!9 It is not yet clear whether this reflects
the effects of alcohol alone, and some patients may in fact
have concomitant viral hepatitis, which-is probably due to
HCV in most cases, though as yet uncharacterised non-B,
non-C viruses may be implicated.3D Increasingly it appears
that alcohol and viral infection may act synergistically to
induce more severe liver disease than can be ascribed to
alcohol alone.
Non-alcoholic steatohepatitis
This disorder is described in patients who take little or no
alcohol but have consistently raised transaminases and
histological changes indistinguishable from those of alcohol-
induced liver injury."·32 These may include fatty change,
portal and globular inflammation and even Mallory's
alcoholic hyaline. Patients are often obese, female and
diabetic, and may be hyperlipidaemic. They tend to be
asymptomatic but may have hepatomegaly and some right
upper quadrant tenderness. Unfortunately there is no reliable
method of distinguishing such patients from those with
alcohol-induced liver disease, and the diagnosis must rely
on the exclusion of alcohol abuse by circumstantial means.
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Metabolic diseases
Wilson's disease may present as CH before the onset of
neurological illness. A reduced plasma caeruloplasmin
concentration33 and a raised hepatic copper concentration
are typical of the condition, but neither alone is specific for
Wilson's disease," although the two together are diagnostic.
In the absence of hepatic copper measurements, the
diagnosis is suggested by the finding of Kayser-Fleischer
rings on ophthalmological slit-lamp examination, reduced
caeruloplasmin concentrations and an increased urinary
copper excretion in excess of 1,6 ~mo1!24 h. 35 The serum
copper value itself is unreliable, and the morphological
appearances on hepatic biopsy, ranging from CH on a
background of micronodular cirrhosis to massive necrosis,
are not specific. The diagnosis of Wilson's disease is not
straightforward and several pitfalls remain to trap the unwary.
Thus severe hepatic necrosis from any cause may cause a
reduced caeruloplasmin level as a result of decreased
synthesis leading to an erroneous diagnosis of Wilson's
disease; patients with PBC or chronic cholestasis may show
Kayser-Fleischer rings, increased hepatic copper
concentrations and an increased urinary copper excretion,'6.37
although the caeruloplasmin yalue will be norma!."
Alpha-1-antitrypsin deficiency will also occasionally
produce features suggestive of CH.'B The diagnosis is
suggested by detecting periodic acid-Schiff-positive
globules in the liver which test positive for (X,-antitrypsin by
immunohistochemical techniques. Further confirmation will
. come from the demonstration of the abnormal (X,-antitrypsin
phenotypes associated with disease, particularly the PiZ
allele. PiZZ homozygotes are most severely affected."
Also to be considered as causes of persistently abnormal
transaminases are the iron overload states, haemosiderosis
and haemochromatosis. The first is common in black South
African males and is often associated with moderately
elevated serum transaminases. A high serum ferritin level
and transferrin saturation are suggestive; since these tests
alone are not specific for iron overload, liver biopsy should
be performed to confirm the diagnosis. Staining for the
pattern and degree of iron deposition is helpful, and
spectrophotometric quantitation of hepatic iron content is
diagnostic.40
Approach to the diagnosis of CH (Table /I)
In most instances history is of limited help. However, in the
case of drug-induced CH it is vital, since there is seldom
evidence to implicate drugs either on physical examination
or on special investigations. For the same reason a history
of alcohol consumption is important; since patients may
deny the amount of alcohol they take, independent
information should be sought from family and colleagues.
Symptoms suggestive of auto-immune disease, such as the
dry eyes and dry mouth of the sicca syndrome, may point to
AICH. Most patients in South Africa with chronic HBV or
HCV infection will not give a history of blood transfusions,
tattooing and other risk factors for parenteral viral
transmission, so a history here is of low sensitivity. An
important aspect of the history, however, is an assessment
of the severity of the disease as manifested by its effects on
the patient; thus marked fatigue or symptoms of early
encephalopathy may point to a severe process.









HBs antigen, HBe antigen, anti HBe antibody
Hepatitis C
Anti-HCV antibody, confirmatory RIBA or PCR
Auto-immune serology




Serum copper, caeruloplasmin, urinary copper excretion
Histology.
Assessment of response to therapy
Physical examination is usually unhelpful in assigning a
cause to CH. There may be no abnormalities at all; other
patients may have nonspecific findings such as
hepatomegaly, jaundice or features of chronic liver disease
such as spider angiomas. However, occasional patients will
show highly diagnostic features such as Kayser-Fleischer
rings in Wilson's disease or pigmentation and arthropathy in
haemochromatosis. Thus one cannot assess a patient with
suspected CH without adequate biochemical and serological
screening.
In the first instance, the presence of hepatitis is confirmed
by demonstrating a sustained or fluctuant elevation of the
transaminases. Disproportionately high alkaline phosphatase
and gamma-glutamyl transpeptidase or 5' -nucleotidase
should arouse suspicion of biliary obstruction or a
cholestatic process such as PBC or PSC; this will require
further investigation, including imaging of the biliary tree and
liver biopsy.
Liver function should be assessed by determining bilirubin
levels, serum albumin and the prothrombin time or
international normalised ratio (INR). Following confirmation
of the presence of chronic hepatitis and an estimation of its
functional severity, further investigations are directed
towards determining the cause.
It is necessary in every case to exclude viral infection. As
a screen, HBs antigen and anti-HCV antibody should be
sought. Where HBs antigen is present, HBV is a likely but
not necessarily definite cause of the CH. Further
confirmation of this must be sought by testing for HBe
antigen and, where possible, HBV DNA levels. Final
confirmation will come from biopsy. A positive HCV antibody
result must be confirmed; preferably by detection of HCV
RNA by PCR, or at least by RIBA or one of the newer
ELlSAs. Here histological changes may also be suggestive.
Serological markers for auto-immune disorders should be
sought. The important tests are the ANA and anti-smooth-
muscle antibodies, which are positive in most cases of
type I AICH. It is not necessary to test the antimitochondrial
antibody unless there are pointers towards PBC. Histological
examination will add useful information. Where the ANA are
11IIIIIIII
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negative and there is a strong suspicion of AICH, anti-LKM
antibodies or positive tests for HCV may suggest type 2
AICH.
In the absence of other positive results metabolic
disorders must be excluded. Serum copper, urinary copper
excretion and plasma caeruloplasmin will help to exclude
Nilson's disease. Serum ferritin and transferrin and a,-
.3.ntitrypsin levels should be determined to exclude iron
storage diseases and a,-antitrypsin deficiency.
In most instances liver biopsy is important. An adequate
:ore is essential to ensure that sufficie.nt representative
-issue is present for a valid assessment to be made. Biopsies
should be interpreted by an experienced pathologist to
Nhom all the patient's clinical and biochemical findings
should be available. Immunohistochemical techniques can
"Je important in confirming a diagnosis; where such expertise
s absent, the specimen should be sent to a centre of
excellence for review. The block itself should accompany the
slides so that further preparation is possible.
Where all diagnostic approaches fail to define an obvious
cause, a 'non-diagnosis' of cryptogenic CH may have to be
llade. It is, however, important to remember that HCV
Infection, HBV infection and AICH will in some cases fail to
yield definitively positive results. Here a trial of steroids
should be undertaken, under strict supervision since viral
CH may advance rapidly on steroid therapy.
In all but the most straightforward cases patients may
benefit from review by a specialist centre interested in liver
disease. It is our experience that many patients referred to
the Liver Clinic of the University of Cape Town for
consideration of a transplant for apparently 'end-stage' liver
disease have on review turned out to have diseases
amenable to medical therapy; in many instances this has
made surgery unnecessary.
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Chronic viral hepatitis caused by hepatitis B, C or 0 may
lead to cirrhosis, hepatocellular failure and hepatocellular
carcinoma. The morbidity of these diseases has
necessitated a prolonged search for effective therapy.
Although many antiviral compounds have been evaluated for
the treatment of chronic viral hepatitis, few have achieved
clinical applicability. Alpha-interferon has been widely
studied, and remains the mainstay of treatment. A number
of other cytokines, including thymosin, are being evaluated.
Nucleoside analogues, alone or in combination with alpha-
interferon, may prove useful adjuncts to the treatment of
chronic hepatitis Band C.
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